Loading...

David R Gandara

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara D, Knollmann FD. CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates. Eur Radiol. 2018 Jun 04. PMID: 29869174.
      View in: PubMed
    2. Zill OA, Banks KC, Fairclough SR, Mortimer S, Vowles JV, Mokhtari R, Gandara D, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018 May 18. PMID: 29776953.
      View in: PubMed
    3. Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R. A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics. Clin Cancer Res. 2018 Apr 23. PMID: 29685883.
      View in: PubMed
    4. Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 Mar 21. PMID: 29773328.
      View in: PubMed
    5. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara D. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 May; 81(5):957-963. PMID: 29520435.
      View in: PubMed
    6. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara D, Mack PC, Cross DAE. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 May; 17(5):885-896. PMID: 29483211.
      View in: PubMed
    7. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara D, Kelly K, Santella RM, Albain KS, Ambrosone CB. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 Jan 13. PMID: 29346580.
      View in: PubMed
    8. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 Feb; 13(2):165-183. PMID: 29175116.
      View in: PubMed
    9. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara D. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan; 19(1):101-114. PMID: 29169877.
      View in: PubMed
    10. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara D, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec; 18(12):1610-1623. PMID: 29129443.
      View in: PubMed
    11. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara D, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    12. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara D. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 Oct; 112:165-168. PMID: 29191590.
      View in: PubMed
    13. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara D. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 Jan; 19(1):84-92. PMID: 28801183.
      View in: PubMed
    14. Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara D, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clin Lung Cancer. 2018 Jan; 19(1):35-41. PMID: 28757336.
      View in: PubMed
    15. Melosky B, Popat S, Gandara D. An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clin Lung Cancer. 2018 Jan; 19(1):42-50. PMID: 28668205.
      View in: PubMed
    16. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara D, Kelly K. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 Aug; 12(8):1299-1308. PMID: 28599887.
      View in: PubMed
    17. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara D, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 Aug; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    18. Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara D, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076. PMID: 28356425.
      View in: PubMed
    19. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara D, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      View in: PubMed
    20. Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y. Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. J Thorac Oncol. 2017 Jul; 12(7):e81-e84. PMID: 28286242.
      View in: PubMed
    21. Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara D, Phinney BS, Fiehn O, Pass H, Miyamoto S. Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. Carcinogenesis. 2017 Jan 03. PMID: 28049629.
      View in: PubMed
    22. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara D, Lara P, Mack PC. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
      View in: PubMed
    23. Gandara D, Riess JW, Kelly K, Li T, Mack PC, Lara PN. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    24. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara D. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 01 21; 389(10066):255-265. PMID: 27979383.
      View in: PubMed
    25. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara D, Kelly K, Mack PC. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):281-285. PMID: 28038979.
      View in: PubMed
    26. Gandara D, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. PMID: 27876675.
      View in: PubMed
    27. Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara D, Date H, Hasegawa S. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 03; 12(3):477-490. PMID: 27867002.
      View in: PubMed
    28. Riess JW, Lara PN, Gandara D. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 Nov 01; 34(31):3717-3718. PMID: 27601544.
      View in: PubMed
    29. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara D, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. PMID: 27919627.
      View in: PubMed
    30. Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara D, Zhang Y, Fiehn O, Pass H, Miyamoto S. Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics. 2016; 13:31. PMID: 27799870.
      View in: PubMed
    31. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 Nov 20; 34(33):3992-3999. PMID: 27646951.
      View in: PubMed
    32. Mack PC, Banks KC, Zill OA, Mortimer SA, Chudova DI, Odegaard J, Lee CE, Nagy RJ, Eltoukhy H, Talasaz A, Lanman R, Gandara D. O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations. J Thorac Oncol. 2016 Oct; 11(10S):S168-S169. PMID: 27676472.
      View in: PubMed
    33. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara D, Lara PN. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. PMID: 27650362.
      View in: PubMed
    34. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 12; 11(12):2066-2081. PMID: 27575423.
      View in: PubMed
    35. Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara D, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 01; 18(1):5-12. PMID: 27473736.
      View in: PubMed
    36. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22. PMID: 27296106.
      View in: PubMed
    37. Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clin Lung Cancer. 2017 01; 18(1):e71-e79. PMID: 27426974.
      View in: PubMed
    38. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara D. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):43-49. PMID: 27461773.
      View in: PubMed
    39. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara D, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. PMID: 27229180.
      View in: PubMed
    40. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara D, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-38. PMID: 27013409.
      View in: PubMed
    41. Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara D, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 06; 34(3):355-63. PMID: 26996385.
      View in: PubMed
    42. Gandara D, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar; 2(3):300-1. PMID: 26720042.
      View in: PubMed
    43. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara D, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. PMID: 26829312; PMCID: PMC4836290 [Available on 04/01/17].
    44. Ruhaak LR, Stroble C, Dai J, Barnett M, Taguchi A, Goodman GE, Miyamoto S, Gandara D, Feng Z, Lebrilla CB, Hanash S. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. Cancer Prev Res (Phila). 2016 Apr; 9(4):317-23. PMID: 26813970; PMCID: PMC4818659 [Available on 04/01/17].
    45. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62. PMID: 26811519.
      View in: PubMed
    46. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara D. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. PMID: 26725184; PMCID: PMC4775366 [Available on 03/01/17].
    47. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara D, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. PMID: 26672084; PMCID: PMC4683399 [Available on 12/15/16].
    48. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara D. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. PMID: 26498504.
      View in: PubMed
    49. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, West HL, Lara PN, Gandara D. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10(10):1421-9. PMID: 25719266.
      View in: PubMed
    50. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. PMID: 26362045; PMCID: PMC4694049 [Available on 11/01/16].
    51. Ferrarotto R, Redman MW, Gandara D, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chin Clin Oncol. 2015 Sep; 4(3):36. PMID: 26408303.
      View in: PubMed
    52. Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, Goodman G, Feng Z, Gandara D, Fiehn O, Taguchi A. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol. 2015 Nov 20; 33(33):3880-6. PMID: 26282655; PMCID: PMC4652011 [Available on 11/20/16].
    53. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara D, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1716-23. PMID: 26282632; PMCID: PMC4633344 [Available on 11/01/16].
    54. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara D, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481; PMCID: PMC4535951.
    55. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. Modern Methods for Delineating Metagenomic Complexity. Cell Syst. 2015 Jul 29; 1(1):6-7. PMID: 27135684.
      View in: PubMed
    56. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics. Cell Syst. 2015 Jul 29; 1(1):97-97.e3. PMID: 27135689.
      View in: PubMed
    57. Gandara D, Lara PN, Mack PC. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. PMID: 26215942.
      View in: PubMed
    58. Hirsch FR, Herbst RS, Gandara D. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncol. 2015 Aug; 16(8):872-3. PMID: 26156654.
      View in: PubMed
    59. Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara D, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227; PMCID: PMC4493926.
    60. Carbone DP, Gandara D, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol. 2015 Jul; 10(7):974-84. PMID: 26134219; PMCID: PMC4618296.
    61. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara D. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395 [Available on 10/01/16].
    62. Gandara D, Hammerman PS, Sos ML, Lara PN, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. PMID: 25979930; PMCID: PMC4862209.
    63. Lara PN, Gandara D, Redman MW. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". J Thorac Oncol. 2015 May; 10(5):e36. PMID: 25898968.
      View in: PubMed
    64. Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara D, Hanash SM, Kim K, Fiehn O. Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites. 2015 Apr 09; 5(2):192-210. PMID: 25859693; PMCID: PMC4495369.
    65. Heigener DF, Gandara D, Reck M. Targeting of MEK in lung cancer therapeutics. Lancet Respir Med. 2015 Apr; 3(4):319-27. PMID: 25801412.
      View in: PubMed
    66. Gandara D, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    67. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara D, Pan CX, Lara PN. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. PMID: 25739672; PMCID: PMC4452427.
    68. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics. Cell Syst. 2015 Jul 29; 1(1):72-87. PMID: 26594662.
      View in: PubMed
    69. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara D, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar; 16(3):257-65. PMID: 25704439.
      View in: PubMed
    70. Herbst RS, Gandara D, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. PMID: 25680375; PMCID: PMC4654466.
    71. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara D, Kelly K, Fiehn O, Miyamoto S. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015 May; 8(5):410-8. PMID: 25657018; PMCID: PMC4618700.
    72. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara D. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. PMID: 25611229; PMCID: PMC4304604.
    73. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara D, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1574-82. PMID: 25589624.
      View in: PubMed
    74. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara D. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. PMID: 25703100; PMCID: PMC4497941.
    75. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara D. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004; PMCID: PMC4320001.
    76. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara D, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2015 Feb 15; 21(4):739-48. PMID: 25516890; PMCID: PMC4335074.
    77. Holland WS, Chinn DC, Lara PN, Gandara D, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. PMID: 25323938; PMCID: PMC4562434.
    78. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara D. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. PMID: 25002722; PMCID: PMC4121504.
    79. Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara D. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg. 2014 Aug; 98(2):402-10. PMID: 24980603.
      View in: PubMed
    80. Lara MS, Brunson A, Wun T, Tomlinson B, Qi L, Cress R, Gandara D, Kelly K. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014 Aug; 85(2):264-9. PMID: 24878033.
      View in: PubMed
    81. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara D. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 01; 120(15):2343-51. PMID: 24752945; PMCID: PMC4140446.
    82. Cooke DT, Gandara D, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. PMID: 24746995.
      View in: PubMed
    83. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara D. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol. 2014 Jan; 9(1):18-25. PMID: 24346090.
      View in: PubMed
    84. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara D. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. PMID: 24189513; PMCID: PMC4072123.
    85. Gandara D, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    86. Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013 Oct; 5 Suppl 5:S556-64. PMID: 24163748; PMCID: PMC3804876.
    87. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara D. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936; PMCID: PMC4562389.
    88. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara D. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. PMID: 24010120; PMCID: PMC3755267.
    89. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013 Sep 20; 31(27):3320-6. PMID: 23980091; PMCID: PMC3770864.
    90. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara D. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    91. Hirsch FR, Gandara D. FASTACT-2: but don't act too fast. Lancet Oncol. 2013 Jul; 14(8):684-5. PMID: 23782815.
      View in: PubMed
    92. Iqbal S, Lenz HJ, Gandara D, Shibata SI, Groshen S, Synold TW, Newman EM. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. PMID: 23712328; PMCID: PMC3779138.
    93. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara D. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. PMID: 23470290.
      View in: PubMed
    94. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. PMID: 23525540; PMCID: PMC3640767.
    95. Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara D, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013 Mar; 8(3):373-84. PMID: 23370315.
      View in: PubMed
    96. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara D. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. PMID: 23415808; PMCID: PMC4567037.
    97. Schiller JH, Gandara D, Goss GD, Vokes EE. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3. PMID: 23401450.
      View in: PubMed
    98. Li T, Kung HJ, Mack PC, Gandara D. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. PMID: 23401433; PMCID: PMC3589700.
    99. Mack PC, Gandara D, Lara PN. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. PMID: 23253224.
      View in: PubMed
    100. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara D, O'Donnell RT. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. PMID: 22986740.
      View in: PubMed
    101. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara D, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987.
      View in: PubMed
    102. Gandara D, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. PMID: 22677432; PMCID: PMC4049356.
    103. Kindler HL, Karrison TG, Gandara D, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
    104. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara D. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012 Aug 01; 18(15):4004-12. PMID: 22592956; PMCID: PMC3409929.
    105. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara D, Adjei AA, Mandrekar SJ. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 2012 Nov 01; 118(21):5358-65. PMID: 22434489; PMCID: PMC3481159.
    106. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara D. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425; PMCID: PMC3288403.
    107. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara D, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. PMID: 22307137.
      View in: PubMed
    108. Mahaffey CM, Mahaffey NC, Holland W, Zhang H, Gandara D, Mack PC, Forman HJ. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 2012 Jan; 7(1):34-9. PMID: 22089114; PMCID: PMC3241903.
    109. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara D. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. PMID: 21892109; PMCID: PMC3219834.
    110. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara D, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. PMID: 22105720; PMCID: PMC3288125.
    111. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara D. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45. PMID: 21964533; PMCID: PMC3477852.
    112. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. PMID: 22015991; PMCID: PMC4131984.
    113. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara D. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
    114. Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara D, Chen A, Kirkwood JM. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81. PMID: 21880788; PMCID: PMC3196047.
    115. Tan EH, Goss GD, Salgia R, Besse B, Gandara D, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed
    116. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara D, Mack PC, Lara PN. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. PMID: 21644050; PMCID: PMC4562405.
    117. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara D. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. PMID: 21517811; PMCID: PMC3272081.
    118. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara D, Frankel P, Pan CX, Lara PN. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. PMID: 21431345.
      View in: PubMed
    119. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223; PMCID: PMC3145006.
    120. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601. PMID: 21270668; PMCID: PMC3643692.
    121. Semrad TJ, Gandara D, Lara PN. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar; 3(2):95-100. PMID: 21789159; PMCID: PMC3126039.
    122. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara D. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. PMID: 21119513.
      View in: PubMed
    123. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20; 29(9):1198-203. PMID: 21300924; PMCID: PMC3083875.
    124. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16. PMID: 21282543.
      View in: PubMed
    125. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011 Jan; 6(1):115-20. PMID: 21107287; PMCID: PMC3075557.
    126. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):139-47. PMID: 21107284; PMCID: PMC3033998.
    127. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara D. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177; PMCID: PMC3777729.
    128. Gandara D, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. PMID: 20975603.
      View in: PubMed
    129. Suga JM, Nguyen DV, Mohammed SM, Brown M, Calhoun R, Yoneda K, Gandara D, Lara PN. Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol. 2010 Nov; 5(11):1772-8. PMID: 20881638.
      View in: PubMed
    130. Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara D. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. PMID: 20881645; PMCID: PMC3676180.
    131. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara D. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. PMID: 20967484; PMCID: PMC3277821.
    132. Morgan RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, Doroshow JH. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs. 2012 Apr; 30(2):723-8. PMID: 20936324; PMCID: PMC3751394.
    133. Hirsch FR, Wynes MW, Gandara D, Bunn PA. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11. PMID: 20926402.
      View in: PubMed
    134. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara D. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. PMID: 20921467; PMCID: PMC3020704.
    135. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010 Oct; 5(10):1706-13. PMID: 20871269.
      View in: PubMed
    136. Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara D. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. PMID: 20737417; PMCID: PMC2994945.
    137. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara D. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. PMID: 20559150; PMCID: PMC2911495.
    138. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara D. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741; PMCID: PMC2952720.
    139. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9. PMID: 20231678; PMCID: PMC2860367.
    140. Gandara D, Mack PC, Li T, Lara PN, Herbst RS. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. PMID: 20681067.
      View in: PubMed
    141. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara D, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. PMID: 20148348; PMCID: PMC4559347.
    142. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara D. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. PMID: 19839922.
      View in: PubMed
    143. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara D. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. PMID: 19884861.
      View in: PubMed
    144. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara D, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62. PMID: 19933908; PMCID: PMC2799233.
    145. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 01; 28(1):29-34. PMID: 19933915; PMCID: PMC2799232.
    146. Wakelee H, Loo BW, Kernstine KH, Putnam JB, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara D. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404. PMID: 19900856.
      View in: PubMed
    147. Gandara D, Mack PC, Li T, Lara PN, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. PMID: 19900855.
      View in: PubMed
    148. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara D, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 01; 28(4):614-9. PMID: 19841321; PMCID: PMC2815996.
    149. Sangha R, Lara PN, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara D. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. PMID: 19808190.
      View in: PubMed
    150. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara D, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 01; 374(9687):379-86. PMID: 19632716; PMCID: PMC4407808.
    151. Gandara D, Simons J. A decade of clinical lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):216. PMID: 19632936.
      View in: PubMed
    152. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara D. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. PMID: 19494788.
      View in: PubMed
    153. Gandara D, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. PMID: 19470925; PMCID: PMC2717760.
    154. Gandara D, Lara PN, Mack P, Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. PMID: 19443333.
      View in: PubMed
    155. Le QT, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara D. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009 Jun 20; 27(18):3014-9. PMID: 19364954; PMCID: PMC2702233.
    156. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara D. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. PMID: 19349543; PMCID: PMC2684855.
    157. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara D, Kung HJ, Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. PMID: 19240653; PMCID: PMC2716757.
    158. Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara D, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1149-55. PMID: 19322566; PMCID: PMC3046108.
    159. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara D, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009 May 01; 27(13):2163-9. PMID: 19307510; PMCID: PMC2674003.
    160. Sangha R, Lara PN, Mack PC, Gandara D. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. PMID: 19532012.
      View in: PubMed
    161. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara D. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016; PMCID: PMC3225398.
    162. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. PMID: 19204194; PMCID: PMC2668551.
    163. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara D. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      View in: PubMed
    164. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara D. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    165. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara D. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan; 4(1):87-92. PMID: 19096312; PMCID: PMC3024911.
    166. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. PMID: 19096314; PMCID: PMC3263397.
    167. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. PMID: 19010874; PMCID: PMC2586993.
    168. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G, Gaspar L, Gandara D, Choy H, Putnam JB. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51. PMID: 19073517.
      View in: PubMed
    169. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara D, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008 Nov 01; 14(21):7138-42. PMID: 18981013; PMCID: PMC3543872.
    170. Gandara D, Lara PN, Natale R, Belani C. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. PMID: 18779609.
      View in: PubMed
    171. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara D. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. PMID: 18779603; PMCID: PMC2653139.
    172. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara D, Rosell R, Jablons DM. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 01; 14(17):5565-70. PMID: 18765549.
      View in: PubMed
    173. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara D. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. PMID: 18758306; PMCID: PMC3523698.
    174. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Wagman SD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara D. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol. 2008 Aug; 31(4):317-22. PMID: 18845988.
      View in: PubMed
    175. Chee KG, Nguyen DV, Brown M, Gandara D, Wun T, Lara PN. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008 Jul 28; 168(14):1541-9. PMID: 18663166.
      View in: PubMed
    176. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara D. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7. PMID: 18612151; PMCID: PMC3368372.
    177. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara D, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42. PMID: 18520298.
      View in: PubMed
    178. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. PMID: 18525299.
      View in: PubMed
    179. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20; 26(21):3543-51. PMID: 18506025.
      View in: PubMed
    180. Xiao GG, Zhou BS, Somlo G, Portnow J, Juhasz A, Un F, Chew H, Gandara D, Yen Y. Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy. Cancer Genomics Proteomics. 2008 May-Aug; 5(3-4):151-60. PMID: 18820369.
      View in: PubMed
    181. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara D, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55. PMID: 18449013; PMCID: PMC3374724.
    182. Calhoun R, Jablons D, Lau D, Gandara D. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity. Oncology (Williston Park). 2008 Apr 30; 22(5):511-6; discussion 516, 521-3. PMID: 18533401.
      View in: PubMed
    183. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara D, Mack PC, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. PMID: 18381431.
      View in: PubMed
    184. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara D. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. PMID: 18378568.
      View in: PubMed
    185. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara D. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. PMID: 18347165.
      View in: PubMed
    186. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara D. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91. PMID: 18501094.
      View in: PubMed
    187. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara D. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. PMID: 18202421.
      View in: PubMed
    188. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. PMID: 18165643.
      View in: PubMed
    189. Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara D, Davis SW, Wun T, Chen MS, Lara PN. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008 Jan 01; 112(1):212-9. PMID: 18008353.
      View in: PubMed
    190. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara D. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. PMID: 18166843.
      View in: PubMed
    191. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):35-8. PMID: 18282356.
      View in: PubMed
    192. Gautschi O, Mack PC, Davies AM, Jablons DM, Rosell R, Gandara D. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2008; 9 Suppl 3:S129-38. PMID: 19419927.
      View in: PubMed
    193. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara D. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15. PMID: 18282352.
      View in: PubMed
    194. Sangha R, Lara PN, Mack P, Gandara D. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. PMID: 19419929.
      View in: PubMed
    195. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara D. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    196. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara D, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    197. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara D. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. PMID: 18186959.
      View in: PubMed
    198. Gandara D, Sangha R, Davies AM. Bevacizumab: optimal dose, schedule, and duration of therapy. Clin Lung Cancer. 2007 Nov; 8(9):522-3. PMID: 18186957.
      View in: PubMed
    199. Davies AM, Lara PN, Mack PC, Gandara D. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. PMID: 17671158.
      View in: PubMed
    200. Gandara D, Wakelee H, Calhoun R, Jablons D. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007 Jul; 2(7 Suppl 3):S125-7. PMID: 17603308.
      View in: PubMed
    201. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007 Jul 01; 25(19):2747-54. PMID: 17602080.
      View in: PubMed
    202. Ho C, Davies A, Mack P, Gandara D. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clin Lung Cancer. 2007 Jul; 8(7):420-4. PMID: 17681094.
      View in: PubMed
    203. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007 Jun 15; 13(12):3660-6. PMID: 17575231.
      View in: PubMed
    204. Garland LL, Rankin C, Gandara D, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007 Jun 10; 25(17):2406-13. PMID: 17557954.
      View in: PubMed
    205. Hesketh PJ, Lilenbaum RC, Chansky K, Dowlati A, Graham P, Chapman RA, Crowley JJ, Gandara D. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol. 2007 Jun; 2(6):494-8. PMID: 17545843.
      View in: PubMed
    206. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara D. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007 Jun; 2(6):526-30. PMID: 17545848.
      View in: PubMed
    207. Yoneda KY, Shelton DK, Beckett LA, Gandara D. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun; 2(6):537-43. PMID: 17545850.
      View in: PubMed
    208. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara D. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. PMID: 17508219.
      View in: PubMed
    209. Raz DJ, Zell JA, Ou SH, Gandara D, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007 Jul; 132(1):193-9. PMID: 17505036.
      View in: PubMed
    210. Hesketh PJ, Chansky K, Israel V, Grapski RT, Mekhail TM, Spiridonidis CH, Mills GM, Kelly K, Crowley JJ, Gandara D. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol. 2007 May; 2(5):440-4. PMID: 17473660.
      View in: PubMed
    211. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara D. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. PMID: 17440682.
      View in: PubMed
    212. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara D, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May; 25(3):182-8. PMID: 17530488.
      View in: PubMed
    213. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. Oncologist. 2007 Mar; 12(3):331-7. PMID: 17405898.
      View in: PubMed
    214. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. PMID: 17410032.
      View in: PubMed
    215. Gandara D, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    216. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007 Jan 20; 25(3):313-8. PMID: 17235046.
      View in: PubMed
    217. Yoneda KY, Hardin KA, Gandara D, Shelton DK. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer. 2006 Dec; 8 Suppl 1:S31-5. PMID: 17239288.
      View in: PubMed
    218. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara D. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20; 24(33):5242-6. PMID: 17114656.
      View in: PubMed
    219. Gandara D, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. PMID: 17409997.
      View in: PubMed
    220. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara D. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5. PMID: 17409984.
      View in: PubMed
    221. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara D. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. PMID: 17409985.
      View in: PubMed
    222. Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemother Pharmacol. 2007 Mar; 59(4):549-57. PMID: 17051371.
      View in: PubMed
    223. Gandara D, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. PMID: 17026812.
      View in: PubMed
    224. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara D. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. PMID: 17026809.
      View in: PubMed
    225. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara D. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006 Jul; 1(6):537-44. PMID: 17409914.
      View in: PubMed
    226. Wakelee HA, Schiller JH, Gandara D. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006 Jul; 8(1):18-21. PMID: 16870041.
      View in: PubMed
    227. Gandara D, Davies AM. Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. J Clin Oncol. 2006 Jun 20; 24(18):2700-1. PMID: 16682720.
      View in: PubMed
    228. Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 2006 May; 15(5):1299-304. PMID: 16596201.
      View in: PubMed
    229. Ho C, Davies AM, Lara PN, Gandara D. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer. 2006 May; 7 Suppl 4:S118-25. PMID: 16764752.
      View in: PubMed
    230. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara D. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. PMID: 16800963.
      View in: PubMed
    231. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara D. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006 Apr 20; 24(12):1807-13. PMID: 16622257.
      View in: PubMed
    232. Williamson SK, McCoy SA, Gandara D, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol. 2006 Apr; 29(2):116-22. PMID: 16601427.
      View in: PubMed
    233. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara D. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006 Mar 20; 24(9):1428-34. PMID: 16549837.
      View in: PubMed
    234. Lara PN, Gandara D, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. PMID: 16640809.
      View in: PubMed
    235. Gandara D. Bronchioloalveolar carcinoma: the "changing face of lung cancer". Clin Lung Cancer. 2006 Mar; 7(5):299. PMID: 16640799.
      View in: PubMed
    236. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara D. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      View in: PubMed
    237. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara D. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
      View in: PubMed
    238. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara D. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. PMID: 16361616.
      View in: PubMed
    239. Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara D, Wun T, Beckett LA, Chen MS. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005 Dec 20; 23(36):9282-9. PMID: 16361626.
      View in: PubMed
    240. Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara D, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006 Jan 01; 24(1):141-4. PMID: 16330670.
      View in: PubMed
    241. Gandara D, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. PMID: 16384543.
      View in: PubMed
    242. Gandara D, Hesketh P. Treatment options for patients with advanced-stage non-small-cell lung cancer: who are the "elderly" and who are the "unfit"? Clin Lung Cancer. 2005 Nov; 7(3):154-5. PMID: 16354308.
      View in: PubMed
    243. Davies AM, Lara PN, Mack PC, Gumerlock PH, Bold RJ, Gandara D. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. PMID: 16250929.
      View in: PubMed
    244. Lara PN, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara D. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. PMID: 16250931.
      View in: PubMed
    245. Gandara D, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol. 2005 Sep 01; 23(25):5856-8. PMID: 16043825.
      View in: PubMed
    246. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara D. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45. PMID: 15998906.
      View in: PubMed
    247. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara D, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
      View in: PubMed
    248. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. PMID: 16000614.
      View in: PubMed
    249. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23; 352(25):2589-97. PMID: 15972865.
      View in: PubMed
    250. Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara D. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. PMID: 15958629.
      View in: PubMed
    251. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara D. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005 May 01; 23(13):2955-61. PMID: 15860851.
      View in: PubMed
    252. Turrisi AT, Crowley J, Albain K, Gaspar L, Gandara D. Southwest Oncology Group: two decades of experience in non-small cell lung cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S119-21. PMID: 16015548.
      View in: PubMed
    253. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar; 6(5):281-6. PMID: 15845178.
      View in: PubMed
    254. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara D. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. PMID: 15711184.
      View in: PubMed
    255. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara D. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004 Dec; 28(6):548-56. PMID: 15589080.
      View in: PubMed
    256. Mack PC, Jones AA, Gustafsson MH, Gandara D, Gumerlock PH, Goldberg Z. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004 Dec; 162(6):623-34. PMID: 15548112.
      View in: PubMed
    257. Lau D, Guo L, Gandara D, Young LJ, Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs. 2004 Oct; 15(9):871-5. PMID: 15457127.
      View in: PubMed
    258. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara D, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    259. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara D. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. PMID: 15476595.
      View in: PubMed
    260. Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara D. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004 Aug 15; 10(16):5418-24. PMID: 15328179.
      View in: PubMed
    261. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara D. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004 Aug 01; 10(15):5022-6. PMID: 15297403.
      View in: PubMed
    262. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara D, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s. PMID: 15217958.
      View in: PubMed
    263. Gandara D, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. PMID: 15217959.
      View in: PubMed
    264. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol. 2004 Oct; 54(4):283-9. PMID: 15184995.
      View in: PubMed
    265. Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara D, Gumerlock PH. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci. 2004 Jun; 1022:55-60. PMID: 15251940.
      View in: PubMed
    266. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara D. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15; 100(10):2125-31. PMID: 15139054.
      View in: PubMed
    267. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol. 2004 May; 50(2):111-9. PMID: 15157660.
      View in: PubMed
    268. Davies AM, Lara PN, Lau DH, Gandara D. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. PMID: 15094177.
      View in: PubMed
    269. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara D. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. PMID: 19777702.
      View in: PubMed
    270. Liu G, Gandara D, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. PMID: 14871968.
      View in: PubMed
    271. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara D. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. PMID: 14981579.
      View in: PubMed
    272. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara D. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol. 2004 Jan 01; 22(1):127-32. PMID: 14701775.
      View in: PubMed
    273. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara D. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. PMID: 14967075.
      View in: PubMed
    274. Gandara D. Developing targeted therapies for lung cancer. Clin Adv Hematol Oncol. 2003 Nov; 1(11):648-9, 690. PMID: 16258461.
      View in: PubMed
    275. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara D, Benfield JR. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. PMID: 14666039.
      View in: PubMed
    276. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara D. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
      View in: PubMed
    277. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara D. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. PMID: 14555506.
      View in: PubMed
    278. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003 Aug; 30(4 Suppl 15):14-9. PMID: 14523790.
      View in: PubMed
    279. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara D. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. PMID: 12867067.
      View in: PubMed
    280. Wild CA, Wang SE, Gandara D, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. PMID: 12886868.
      View in: PubMed
    281. Gandara D, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10. PMID: 12743155.
      View in: PubMed
    282. Davies AM, Lara PN, Mack PC, Gandara D. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. PMID: 12667118.
      View in: PubMed
    283. Mack PC, Gandara D, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. PMID: 12721762.
      View in: PubMed
    284. Edelman MJ, Gandara D, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):197-9. PMID: 12581573.
      View in: PubMed
    285. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal. 2003; 17(5):184-94. PMID: 12938148.
      View in: PubMed
    286. Davies AM, Gandara D, Lara PN, Mack PC, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. PMID: 14720340.
      View in: PubMed
    287. Perez EA, Gandara D, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. PMID: 12643003.
      View in: PubMed
    288. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara D. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. PMID: 12643004.
      View in: PubMed
    289. Vokes EE, Choy H, Gandara D, Mattson K. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35. PMID: 12480192.
      View in: PubMed
    290. Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2002 Nov; 50(5):353-9. PMID: 12439592.
      View in: PubMed
    291. Albain KS, Crowley JJ, Turrisi AT, Gandara D, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15; 20(16):3454-60. PMID: 12177106.
      View in: PubMed
    292. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara D. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):47-51. PMID: 14653876.
      View in: PubMed
    293. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002 Jul; 8(7):2286-91. PMID: 12114432.
      View in: PubMed
    294. Davies A, Gandara D, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. PMID: 12170446.
      View in: PubMed
    295. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara D. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002 May 15; 94(10):2584-9. PMID: 12173324.
      View in: PubMed
    296. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara D. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. PMID: 14720347.
      View in: PubMed
    297. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara D. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002 Feb 20; 94(4):291-7. PMID: 11854391.
      View in: PubMed
    298. Gandara D, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. PMID: 11894020.
      View in: PubMed
    299. Lara PN, Lau DH, Gandara D. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. PMID: 12057087.
      View in: PubMed
    300. Kuriakose P, Gandara D, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest. 2002; 20(4):473-9. PMID: 12094542.
      View in: PubMed
    301. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. PMID: 12197222.
      View in: PubMed